Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

You may be eligible if

• Inclusion:
• Males and females between the ages of 18 and 75 who are diagnosed with moderate to severe Crohn's Disease defined by a CDAI score of \>= 220 and \<= 450, normal laboratory parameters,
• are willing and able to give informed consent, and
• are able to self-inject or have a designee or healthcare professional who can inject the study medication.
• Exclusion:
• History of certain types of cancer, diagnosis of ulcerative colitis,
• female or breast feeding subjects,
• surgical bowel resection(s) with in the past 6 months,
• history of listeria,
• human immunodeficiency virus (HIV),
• central nervous system demyelinating disease or untreated TB,
• history of a poorly controlled medical condition,
• unsuccessful response to infliximab or any anti-TNF agent use in the past.